XOMA Completes Acquisition of Entire Share Capital of Mural Oncology

XOMA Royalty (XOMA) completed its previously announced acquisition of the entire issued and to be issued share capital of Mural Oncology (MURA) pursuant to an Irish High Court sanctioned scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland. Mural shareholders received $2.035 in cash per share. The Acquisition was approved by Mural shareholders at a special meeting of shareholders convened pursuant to section 450(1) of the Irish Companies Act 2014 and an extraordinary general meeting of shareholders held on October 24, 2025. The Irish High Court sanctioned the Scheme on December 3, 2025. On December 5, 2025, the Scheme and the Acquisition became effective upon delivery of the court order to the Irish Companies Registration Office. Prior to the opening of trading on December 5, 2025, all of Mural's shares will cease trading on Nasdaq, and Mural intends promptly to cause such shares to be delisted from Nasdaq and deregistered under the Securities Exchange Act of 1934, as amended.